Design Therapeutics (DSGN) Operating Expenses (2020 - 2026)

Design Therapeutics (DSGN) has 7 years of Operating Expenses data on file, last reported at $19.7 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 3.49% year-over-year to $19.7 million; the trailing twelve-month figure through Mar 2026 stood at $78.8 million (up 15.14% YoY), and the FY2025 full-year result was $79.5 million, up 27.39% from the prior year.
• Operating Expenses rose to $19.7 million in Q1 2026, from $18.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $22.6 million in Q2 2023 to a low of $13.4 million in Q1 2022.
• A 5-year average of $18.1 million and a median of $18.8 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses soared 135.39% in 2022 and slumped 33.49% in 2024, its largest moves.
• Tracing DSGN's Operating Expenses over 5 years: stood at $19.4 million in 2022, then decreased by 22.02% to $15.1 million in 2023, then grew by 10.4% to $16.7 million in 2024, then gained by 8.84% to $18.2 million in 2025, then gained by 8.46% to $19.7 million in 2026.
• Business Quant data shows DSGN's Operating Expenses at $19.7 million in Q1 2026, $18.2 million in Q4 2025, and $19.3 million in Q3 2025.